autolus
therapeutics
presents
additional
data
dlbcl
esmo
virtual
congress
shows
promise
highly
differentiated
product
profile
conference
call
webcast
held
friday
september
edt
pm
bst
london
globe
newswire
autolus
therapeutics
plc
nasdaq
autl
biopharmaceutical
company
developing
programmed
cell
therapies
today
announced
new
data
highlighting
progress
company
car
cell
therapy
investigated
alexander
study
phase
clinical
trial
relapsed
refractory
diffuse
large
b
cell
lymphoma
dlbcl
european
society
medical
oncology
esmo
virtual
congress
beginning
september
today
presented
data
recommended
phase
dose
cohort
alexander
trial
dual
targeting
car
product
candidate
dlbcl
data
support
best
class
profile
high
level
complete
remissions
well
tolerated
safety
profile
said
christian
itin
chairman
chief
executive
officer
autolus
tolerable
favorable
safety
profile
compared
approved
car
therapies
said
dr
craig
moskowitz
professor
medicine
miller
school
medicine
university
miami
health
system
promising
complete
response
rate
demonstrated
completed
cohorts
recommended
phase
dose
range
thus
far
complete
remissions
also
appear
durable
among
dose
cohorts
median
follow
months
patients
achieved
complete
response
data
date
august
patients
alexander
phase
clinical
trial
treated
evaluable
safety
well
tolerated
grade
higher
cytokine
release
syndrome
crs
primary
infusion
low
rates
neurotoxicity
nt
across
patients
three
cases
nt
reported
two
grade
among
patients
treated
dose
x
cells
pembrolizumab
day
minus
declared
recommended
phase
dose
one
patient
experienced
nt
patient
died
due
disease
progression
multiorgan
failure
none
patients
achieving
complete
response
cr
experienced
nt
cases
nt
reported
atypical
nature
seen
setting
disease
progression
confounding
factors
terms
efficacy
data
patients
dosed
date
patients
evaluable
within
completed
cohort
cohort
receiving
dose
x
cells
pembrolizumab
objective
response
rate
orr
cr
rate
patients
study
across
dose
levels
evaluable
orr
cr
rate
investor
call
friday
september
management
host
conference
call
webcast
today
edt
pm
bst
discuss
esmo
data
listen
webcast
view
accompanying
slide
presentation
please
go
https
events
call
may
also
accessed
dialing
canada
callers
international
callers
please
ask
joined
autolus
therapeutics
call
conference
call
replay
available
one
year
autolus
website
autolus
therapeutics
plc
autolus
biopharmaceutical
company
developing
programmed
cell
therapies
treatment
cancer
using
broad
suite
proprietary
modular
cell
programming
technologies
company
engineering
precisely
targeted
controlled
highly
active
cell
therapies
designed
better
recognize
cancer
cells
break
defense
mechanisms
eliminate
cells
autolus
pipeline
product
candidates
development
treatment
hematological
malignancies
solid
tumors
information
please
visit
programmed
cell
therapy
containing
two
independent
chimeric
antigen
receptors
targeting
independently
optimized
single
target
activity
simultaneously
targeting
two
b
cell
antigens
designed
minimize
relapse
due
single
antigen
loss
patients
b
cell
malignancies
currently
tested
diffuse
large
b
cell
lymphoma
alexander
clinical
trial
cohort
initiated
assess
feasibility
treatment
outpatient
setting
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
statements
historical
facts
cases
identified
terms
may
could
expects
plans
anticipates
believes
statements
include
limited
statements
regarding
efficacy
safety
therapeutic
potential
future
clinical
development
including
progress
expectations
reporting
data
conduct
timing
statements
based
management
current
views
assumptions
involve
risks
uncertainties
could
cause
actual
results
performance
events
differ
materially
expressed
implied
statements
risks
uncertainties
include
limited
risks
autolus
preclinical
clinical
programs
advance
result
approved
products
timely
cost
effective
basis
results
early
clinical
trials
always
predictive
future
results
cost
timing
results
clinical
trials
many
product
candidates
become
approved
drugs
timely
cost
effective
basis
ability
enroll
patients
clinical
trials
possible
safety
efficacy
concerns
impact
ongoing
pandemic
autolus
business
discussion
risks
uncertainties
important
factors
could
cause
autolus
actual
results
differ
contained
statements
see
section
titled
risk
factors
autolus
annual
report
form
filed
securities
exchange
commission
march
amended
well
discussions
potential
risks
uncertainties
important
factors
autolus
subsequent
filings
securities
exchange
commission
information
press
release
date
release
company
undertakes
obligation
publicly
update
statement
whether
result
new
information
future
events
otherwise
except
required
law
contact
lucinda
crabtree
phd
vice
president
investor
relations
corporate
communications
julia
wilson
